Wainua (Eplontersen)

Wainua (Eplontersen)

Product

by Ionis Pharmaceuticals and AstraZeneca

Heard in 1 episode across 1 show since Jul 2026

Wainua (eplontersen) is a prescription medication used for the treatment of polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adults. Developed by Ionis Pharmaceuticals and AstraZeneca, it is a transthyretin-directed antisense oligonucleotide designed to reduce the production of mutant and wild-type TTR protein.

Episodes

1
across 1 show

First heard

Jul 2026

Expert statements

2
1 positive · 1 negative

Episodes per month

Public PodLume episodes featuring it, over the last year.

Show the data
MonthEpisodes
Dec 20250
Jan 20260
Feb 20260
Mar 20260
Apr 20260
May 20260
Jun 20260
Jul 20261
Aug 20260
Sep 20260
Oct 20260
Nov 20260

Email alert

Email me when Wainua (Eplontersen) comes up on a podcast

One email a week at most, with the new episodes that mention Wainua (Eplontersen). Free, no account needed, unsubscribe in one click.

What experts have said about Wainua (Eplontersen)

2 statements · 1 positive · 1 negative

  1. Chloe MillayNegativeJul 9, 2026· Stock Movers

    Wainua failed to reduce cardiovascular events or related deaths.

    “Wainua did not manage to do that and to reduce cardiovascular events or death related to heart problems”

    Listen at 3:03

    Open the episode · Deutz Buy, Astrazeneca's Trial, Computacenter Up
  2. Chloe MillayPositiveJul 9, 2026· Stock Movers

    A successful Wainua trial could have generated billions in additional sales.

    “a successful trial could have led to billions of dollars more in sales”

    Listen at 3:15

    Open the episode · Deutz Buy, Astrazeneca's Trial, Computacenter Up

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

1 episode featuring Wainua (Eplontersen), newest first